Inhibition of liver fibrosis using vitamin A-coupled liposomes to deliver matrix metalloproteinase-2 siRNA in vitro

Molecular Medicine Reports

Volumn 12, Issue 3, 2015, Pages 3453-3461

  Li, Yiping ^a   Liu, Feng ^a   Ding, Fengan ^a   Chen, Pingsheng ^a   Tang, Meng ^a  

^a SOUTHEAST UNIVERSITY   (China)

Author keywords

Cationic liposomes; Hepatic stellate cells; Liver fibrosis; Matrix metalloproteinase 2; Small interference RNA

Indexed keywords

1,2 DIOLEOYL SN GLYCERO 3 PHOSPHOETHANOLAMINE; 3BETA [N (N',N' DIMETHYLAMINOETHANE) CARBAMOYL] CHOLESTEROL; 4',6 DIAMIDINO 2 PHENYLINDOLE; ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; GELATINASE A; LIPOSOME; RETINOL; UNCLASSIFIED DRUG; MMP2 PROTEIN, RAT; SMALL INTERFERING RNA;

ANIMAL CELL; ARTICLE; CELL ACTIVATION; CELL FUNCTION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; EXTRACELLULAR MATRIX; GENE SILENCING; IN VITRO STUDY; LIPOSOMAL GENE DELIVERY SYSTEM; LIVER FIBROSIS; NONHUMAN; NONVIRAL GENE THERAPY; PARTICLE SIZE; PHYSICAL CHEMISTRY; PROTEIN EXPRESSION; RAT; STELLATE CELL; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL; ZYMOGRAPHY; ANIMAL; APOPTOSIS; CELL LINE; GENETIC TRANSFECTION; GENETICS; LIVER CIRRHOSIS; METABOLISM; RNA INTERFERENCE;

ANIMALS; APOPTOSIS; CELL LINE; GENE KNOCKDOWN TECHNIQUES; LIPOSOMES; LIVER CIRRHOSIS; MATRIX METALLOPROTEINASE 2; RATS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSFECTION; VITAMIN A;

EID: 84935418670     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.3842     Document Type: Article

References (27)

1. Povero D, Busletta C, Novo E, et al: Liver fibrosis: a dynamic and potentially reversible process. Histol Histopathol 25:1075-1091, 2010.
2. Ismail M H and Pinzani M: Reversal of hepatic fibrosis: pathophysiological basis of antifibrotic therapies. Hepat Med 3:69-80, 2011.
3. Novo E, Cannito S, Paternostro C, Bocca C, Miglietta A and Parola M: Cellular and molecular mechanisms in liver fibrogenesis. Arch Biochem Biophys 548:20-37, 2014.
4. Hu YB, Li DG and Lu HM: Modified synthetic siRNA targeting tissue inhibitor of metalloproteinase-2 inhibits hepatic fibrogenesis in rats. J Gene Med 9:217-229, 2007.
5. Mormone E, George J and Nieto N: Molecular pathogenesis of hepatic fibrosis and current therapeutic approaches. Chem Biol Interact 193:225-231, 2011.
6. Radbill BD, Gupta R, Ramirez MC, et al: Loss of matrix metalloproteinase-2 amplifies murine toxin-induced liver fibrosis by upregulating collagen I expression. Dig Dis Sci 56:406-416, 2011.
7. Kong D, Zhang F, Zhang Z, Lu Y and Zheng S: Clearance of activated stellate cells for hepatic fibrosis regression: molecular basis and translational potential. Biomed Pharmacother 67:246-250, 2013.
8. Balazs DA and Godbey W: Liposomes for use in gene delivery. J Drug Deliv 2011:326497-326508, 2011.
9. Kocabayoglu P and Friedman SL: Cellular basis of hepatic fibrosis and its role in inflammation and cancer. Front Biosci (Schol Ed) 5:217-230, 2013.
10. Puche JE, Saiman Y and Friedman SL: Hepatic stellate cells and liver fibrosis. Compr Physiol 3:1473-1492, 2013.
11. Senoo H, Yoshikawa K, Morii M, Miura M, Imai K and Mezaki Y: Hepatic stellate cell (vitamin A-storing cell) and its relative-past, present and future. Cell Biol Int 34:1247-1272, 2010.
12. Fan RH, Chen PS, Zhao D and Zhang WD: Hypoxia induced by CoCl2 influencing the expression and the activity of matrix metalloproteinase-2 in rat hepatic stellate cells. Zhonghua Gan Zang Bing Za Zhi 15:654-657, 2007 (In Chinese).
13. Lee UE and Friedman SL: Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol 25:195-206, 2011.
14. Kumar M and Sarin SK: Is cirrhosis of the liver reversible? Indian J Pediatr 74:393-399, 2007.
15. Gressner AM: Transdifferentiation of hepatic stellate cells (Ito cells) to myofibroblasts: a key event in hepatic fibrogenesis. Kidney Int Suppl 54(Suppl):39-45, 1996.
16. Senoo H, Hata R, Nagai Y and Wake K: Stellate cells (vitamin A-storing cells) are the primary site of collagen synthesis in non-parenchymal cells in the liver. Biomed Res 5:451-458, 1984.
17. Enzan H, Himeno H, Iwamura S, et al: Immunohistochemical identification of Ito cells and their myofibroblastic transformation in adult human liver. Virchows Arch 424:249-256, 1994.
18. Schuppan D and Afdhal NH: Liver cirrhosis. Lancet 371:838-851, 2008.
19. Arthur MJ, Friedman SL, Roll FJ and Bissell DM: Lipocytes from normal rat liver release a neutral metalloproteinase that degrades basement membrane (type iv) collagen. J Clin Invest 84:1076-1085, 1989.
20. Li J, Niu JZ, Wang JF, Li Y and Tao XH: Pathological mechanisms of alcohol-induced hepatic portal hypertension in early stage fibrosis rat model. World J Gastroenterol 11:6483-6488, 2005.
21. Li J, Fan R, Zhao S, et al: Reactive oxygen species released from hypoxic hepatocytes regulates MMP-2 expression in hepatic stellate cells. Int J Mol Sci 12:2434-2447, 2011.
22. Domitrovic R, Jakovac H, Marchesi VV and Blažekovic B: Resolution of liver fibrosis by isoquinoline alkaloid berberine in CCl4-intoxicated mice is mediated by suppression of oxidative stress and upregulation of MMP-2 expression. J Med Food 16:518-528, 2013.
23. Schroeder A, Levins CG, Cortez C, Langer R and Anderson DG: Lipid-based Nano therapeutics for siRNA delivery. J Intern Med 267:9-21, 2010.
24. Wasungu L and Hoekstra D: Cationic lipids, lipoplexes and intracellular delivery of genes. J Control Release 116:255-264, 2006.
25. Sato Y, Murase K, Kato J, et al: Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen specific chaperone. Nat Biotechnol 26:431-442, 2008.
26. Vogel S, Piantedosi R, Frank J, et al: An immortalized rat liver stellate cell line (HSC-T6): a new cell model for the study of retinoid metabolism in vitro. J Lipid Res 41:882-893, 2000.
27. Kawada N: Evolution of hepatic fibrosis research. Hepatol Res 41:199-208, 2011.